Home SMART 100 2018 ResistancePlus MG

ResistancePlus MG [SMART 100, 2018]

0

This SMART 100 profile and the information it contains is a duplication of content submitted by the applicant during the entry process. As a function of entry, applicants were required to declare that all details are factually correct, do not infringe on another’s intellectual property and are not unlawful, threatening, defamatory, invasive of privacy, obscene, or otherwise objectionable. Some profiles have been edited for reasons of space and clarity.

Learn more about the SMART 100 >>

1. THE BEGINNING

This innovation initially came to life when…

Two researchers at the Johnson & Johnson Australia research facility were exploring ways to exploit DNAzymes for diagnostic applications. They came up with a simple, highly effective and flexible innovation. When the laboratory was closed in the GFC, Alison and Elisa managed to find private investors willing to support them as they started their own company, gaining the intellectual property rights from J&J. Working closely with sexual health.

2. WHAT & HOW

The purpose of this innovation is to…

…test for the presence of a bacterial sexually transmitted infection, Mycoplasma genitalium, Mgen (a new STD more prevalent than gonorrhoea) as well as genetic markers that confer resistance to the frontline antibiotic treatment, azithromycin.

It does this by…

…detecting the DNA of the bacteria as well as 5 different DNA mutations. Clinical laboratories can run this diagnostic test using common laboratory equipment. The test includes a simple software program to easily analyse the test results. If mutations are detected then the clinician is notified that their patient has a resistant infection and should receive the second-line treatment option.

3. PURPOSE & BENEFITS

This innovation improves on what came before because…

It allows for Resistance Guided Therapy. Combining the detection of an infection with actionable information about which drug to treat it. This is a game changer in the management of antibiotic resistant STDs.

Its various benefits to the customer/end-user include…

Ensuring patients receive the correct treatment upfront which saves time for the patient, extra testing for the clinic, and extra money for health services. It reduces the spread of resistant infections and enables stewardship of frontline therapy.

4. COMPETITIVE LANDSCAPE

In the past, this problem was solved by…

Laboratories had to develop their own tests that were expensive and time consuming and not readily available. Infections like Mgen were commonly treated based on symptoms only, which led to over-prescription of the front-line drug and development of further antibiotic resistance.

Two companies in Europe released similar products, but the majority of technology cannot easily handle the complex and multiple targets that need to be detected in a single test, thus ResistancePlus MG is a market first and a market leader.

 

5. TARGET MARKET

It is made for…

Clinical diagnostic laboratories to test human samples. A patient will attend a sexual health centre or GP and may exhibit typical symptoms of urethritis, pelvic pain, or discharge. The doctor will take a urine sample or swab and send it to the laboratory for testing. Current guidelines recommend testing all symptomatic patients for Mgen, and guidelines in Australia for the management of Mgen now also recommend to test for antibiotic resistance to guide treatment decisions.

It is available for sale through…

Direct sales in Australia, New Zealand and the UK, and distributor channels throughout EU. This is a clinical diagnostic requiring regulatory approval. ResistancePlus MG is CE marked and TGA approved and currently going through FDA for sale in the US.

Our marketing strategy is to…

Educate doctors and clinicians on the value of a Resistance Guided Therapy approach, as well as providing clinical laboratories with the tools and resources they need to adopt the new test. Further awareness in the general community comes through educational videos and mainstream media talking about Mgen as a new STD and the rise in antibiotic resistance.

 

FINE PRINT: This SMART 100 profile and the information it contains is a duplication of content submitted by the applicant during the entry process. As a function of entry, applicants were required to declare that all details are factually correct, do not infringe on another’s intellectual property and are not unlawful, threatening, defamatory, invasive of privacy, obscene, or otherwise objectionable. Some profiles have been edited for reasons of space and clarity.

Maven Judge Vote: ResistancePlus MG – Smart 100 2018
(Please note – The form below is for judging purposes only and is restricted to the public)

Get unlimited access to our FREE business tools…

Need to raise capital? Want to become a more persuasive presenter? Want to master social media? Is it time to overhaul your website? Unlock the library to get free access to free cheat sheets and business tools. Click here for free business tools.